Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EU Pharmaceutical Industry Starting to Incorporate More QbD-Like Elements in Applications; EU Inspectors Looking to Align Inspections with New Paradigm

This article was originally published in The Gold Sheet

Executive Summary

Quality by Design is advancing in Europe as manufacturers incorporate more QbD elements into their applications and EU regulators begin adjusting their inspections to address QbD-related issues. Decentralized review for most applications slows advance of QbD. Discussion of mock submissions spurs interest. EMEA/EFPIA meeting focuses on QbD issues companies raised privately. PDA launches PCMO initiative for sharing best practices. The increasing pain of over-inspections.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS000443

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel